These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 8555442)

  • 1. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130.
    Xu F; Yu Y; Bast RC; Cornélissen G; Fujii S; Takagi M; O'Brien T; Halberg F
    In Vivo; 1995; 9(4):407-12. PubMed ID: 8555442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectral differences between epitopes in the cronomes of salivary CA130 and CA125.
    Portela A; Cornélissen G; Halberg F; Bast RC; Fujii S; Xu F; Yu Y; Takagi M; Halberg J; Halberg F
    In Vivo; 1995; 9(4):341-6. PubMed ID: 8555433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
    Elg S; Halberg E; Ramakrishnan S; Cornélissen G; Haus E; Nicolau G; Carson L; Twiggs L; Long HJ; Halberg F
    Chronobiologia; 1991; 18(4):141-52. PubMed ID: 1687728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian rhythms of the salivary proliferation markers CA130 and CA125 in clinical health.
    Portela A; Cornélissen G; Halberg F; Halberg E; Illera JC; Illera M
    Rev Esp Fisiol; 1995 Jun; 51(2):107-8. PubMed ID: 8532950
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronome of urinary 6-sulfoxy-melatonin excretion, circulating CA125, cancer progression and therapeutic response.
    Cornélissen G; Berg H; Haus E; Halberg F
    In Vivo; 1995; 9(4):375-8. PubMed ID: 8555437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy.
    Cornélissen G; Halberg F; Halberg E; Bingham C; Haus E; Bast RC; Fujii S; Long HJ; Halberg F; Tamura K
    Chronobiologia; 1992; 19(3-4):131-49. PubMed ID: 1362146
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronobiologic aspects of urinary gonadotropin peptide (UGP).
    Cornélissen G; Halberg F; Walker R; Zaslavskaya RM; Fine RL; Haus E
    In Vivo; 1995; 9(4):359-62. PubMed ID: 8555435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
    Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer marker assessment: case report on salivary and urinary CEA.
    Halberg F; Haus E; Lakatua DJ; Antinozzi R; Cornélissen G
    In Vivo; 1995; 9(4):311-4. PubMed ID: 8555430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salivary CA130 with and without unilateral autonomic parotid denervation of rats fed different diets.
    Johnson-Alvares D; Cornélissen G; Portela A; Halberg E; Rudney JD; Yeh CK; Dodds M; Haus E; Schaffer E; Blank M; Halberg F
    In Vivo; 2002; 16(1):25-8. PubMed ID: 11980356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125.
    Halberg E; Long HJ; Cornélissen G; Blank MA; Elg S; Touitou Y; Bakken E; Delmore P; Haus E; Sackett-Lundeen L
    Chronobiologia; 1992; 19(1-2):17-42. PubMed ID: 1352750
    [No Abstract]   [Full Text] [Related]  

  • 12. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
    van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
    Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Macrophage-colony stimulating factor and ovarian cancer].
    Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
    Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
    Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
    Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
    Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
    Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
    Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
    Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OVX1 as a marker for early stage endometrial carcinoma.
    Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
    Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.